Previous 10 | Next 10 |
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases...
2023-05-17 16:12:00 ET Biotechnology company Cabaletta Bio ( NASDAQ: CABA ) said on Wednesday that it commenced an underwritten public offering of shares. The company is offering all the shares. Additionally, the company intends to grant the underwriters a 30-day option to...
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases...
– Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet Rheumatology publication – – Second IND clearance for CABA-201, ...
2023-05-11 09:41:16 ET Cabaletta Bio press release ( NASDAQ: CABA ): Q1 GAAP EPS of -$0.45 beats by $0.02 . As of March 31, 2023, Cabaletta had cash and cash equivalents of $93.8 million, compared to $106.5 million as of December 31, 2022. The Company expects that ...
– IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and improve disease activity in patients with LN and SLE – – Phase 1/2 tri...
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific O...
Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved -3.68% on the day to $10.98. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B...
2023-05-01 07:40:28 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Cabaletta Bio's ( NASDAQ: CABA ) CABA-201 The drug is being developed to treat patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). SLE is an aut...
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administratio...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...